

## Celgene - Waiting for More Positives...

<https://marketpublishers.com/r/CDDA29719CDEN.html>

Date: August 2012

Pages: 3

Price: US\$ 140.00 (Single User License)

ID: CDDA29719CDEN

### Abstracts

Celgene's (CELG) 2Q12 results lifted the gloom around news related to Revlimid's approval in EU in Newly Diagnosed Multiple Myeloma (NDMM) / 1st-line and maintenance setting. While sales were in line with expectations, we expect further ramp up next year due to Revlimid's geographic expansion. Beyond geographic expansion's opportunity, emerging role of Revlimid in other hematological indications, lymphoma and leukemia, should buffer some setbacks from its pipeline. We maintain our long-term investment thesis based on upcoming potential milestones. An accelerated approval of Onyx's Kyprolis (carfilzomib, R/R MM) should increase the odds of approval of Pomalidomide (an immunomodulatory agent, R, oral, Annexure, est. launch in the US – PDUFA: Feb. 10, 2013 and EU by YE12 / in early 1Q13). However, ... For more detail, please read our report released on 3rd Aug, 2012, titled, "Waiting for More Positives..."

## I would like to order

Product name: Celgene - Waiting for More Positives...

Product link: <https://marketpublishers.com/r/CDDA29719CDEN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CDDA29719CDEN.html>